Bildkälla: Stockfoto

Ossdsign: Strengthening the balance sheet to take on next steps - Redeye

Redeye returns with a review of OssDsign following its announced rights issue and recently presented strategy update – ASCENT25. We are encouraged by its intensified focus on its neurosurgery product portfolio and its new, though adjacent, vertical in spine, strengthening our already favourable view on its longer-term prospects.

Our new Base Case amounts to SEK 19 per share, raised on the back of our updated financial estimates and adjusting for the rights issue. Though we will return with our take on the share’s shorter-term performance, we emphasize that quarterly results are key drivers of the valuation gap, which should be closed in the coming 12 months.
Börsvärldens nyhetsbrev
ANNONSER